FDA approves expanded use of Bristol-Myers’ drug for lung cancer

The U.S. Food and Drug Administration approved the expanded use of Bristol-Myers Squibb Co’s immunotherapy Opdivo to treat patients with advanced non-small cell lung cancer.

Opdivo, whose chemical name is nivolumab, is approved to treat advanced melanoma and a type of non-small cell lung cancer. (1.usa.gov/1JXCpmJ)

Bristol is also testing a combination of Opdivo and its drug Yervoy as a first-line treatment for kidney cancer.

(Reporting by Shailesh Kuber in Bengaluru; Editing by Don Sebastian)